齐格列他/二甲双胍缓释片生物等效性预试验
健康受试者中齐格列他/二甲双胍缓释固定剂量复方片剂的生物等效性预试验:一项随机、开放标签、两周期、单次给药、交叉试验(餐后条件下)
This is a pilot bioequivalence study. It is a randomized, open-label, single-dose, crossover study. The primary objective of this study is to preliminarily evaluate the pharmacokinetic parameters and their variability of the test formulation versus the reference formulation following a single oral dose under fed conditions.
研究概览
地位
条件
研究类型
注册 (实际的)
阶段
- 不适用
联系人和位置
学习地点
-
-
Hunan
-
Yueyang、Hunan、中国、414000
- Hunan Institute of Schistosomiasis Control (Hunan Provincial Third People's Hospital)
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Healthy male or female participants;
- Age from 18 to 45 years, inclusive;
- Body Mass Index (BMI) between 19.0 and 26.0 kg/m² (inclusive). Male participants must weigh at least 50.0 kg, and female participants must weigh at least 45.0 kg;
- From the time of signing the informed consent form until 3 months after the last dose, participants must have no plans for pregnancy or sperm donation and must be willing to use effective contraceptive measures;
- Voluntarily agrees to participate in the study and signs the informed consent form.
Exclusion Criteria:
- Any clinically significant abnormalities in laboratory tests or a history of clinically significant diseases, including but not limited to cardiovascular, cerebrovascular, hepatic, renal, respiratory, gastrointestinal, neurological, hematological, immune, oncological, psychiatric, or endocrine/metabolic disorders;
- Known history of severe allergies (e.g., allergy to more than 3 allergens, allergies affecting the lower respiratory tract such as allergic asthma, allergies requiring glucocorticoid treatment) or a known history of allergy to any component of the investigational products;
- Previous surgery that could affect drug absorption, distribution, metabolism, or excretion (e.g., subtotal gastrectomy), or a history of gastrointestinal, hepatic, or renal disease within the last 6 months that could affect drug absorption or metabolism;
- Surgery within 3 months prior to screening or planned surgery during the study period;
- Received any vaccination within 1 month prior to screening or plan to receive any vaccination during the study period;
- History of infectious disease treated with significant use of antibiotics within 3 months before the first dose, or any infectious disease within 7 days before the first dose;
- Presence of gastrointestinal symptoms (e.g., diarrhea, constipation, nausea, vomiting) within 7 days before the first dose, which the investigator deems unsuitable for study participation;
- Use of any prescription drugs, over-the-counter drugs, or Chinese herbal medicines within 1 month before the first dose; or use of vitamin products within 2 weeks before enrollment;
- History of drug or substance abuse, or a positive alcohol or urine drug screening test;
- Intolerance to venipuncture, or a history of fainting in response to needles or blood;
- Fasting blood glucose > 6.1 mmol/L or < 3.9 mmol/L at screening, and/or a history of hypoglycemia/syncope;
- Participation in any interventional clinical trial within 3 months prior to screening;
- Blood donation or significant blood loss (> 200 mL) within 3 months prior to screening;
- Pregnant or lactating women;
- Weekly alcohol consumption of more than 14 units within 3 months prior to screening, consumption of alcohol within 48 hours before the first dose, or inability to abstain from alcohol during the study;
- Smokes more than 5 cigarettes per day within 3 months prior to screening, has smoked within 48 hours before the first dose, or is unable to abstain from smoking during the study;
- Excessive daily consumption of tea, coffee, and/or caffeinated beverages within 3 months prior to screening, or consumption of such beverages within 48 hours before the first dose;
- Consumption of grapefruit or grapefruit-related citrus fruits (e.g., Seville oranges, pomelos), star fruit, papaya, pomegranate, or their products within 14 days before the first dose;
- Glomerular Filtration Rate (GFR) < 90 mL/min/1.73 m²;
- Systolic blood pressure < 90 mmHg or ≥ 140 mmHg, or diastolic blood pressure < 60 mmHg or ≥ 90 mmHg at screening;
- A positive test result at screening for any of the following: Human Immunodeficiency Virus antibody, Treponema pallidum antibody, Hepatitis B surface antigen, or Hepatitis C virus antibody;
- Inability to comply with the standardized diet (e.g., intolerance to the high-fat meal, lactose intolerance) or has difficulty swallowing;
- Plans to or is required to engage in strenuous physical activity or exercise during the study period;
- Any other condition that, in the opinion of the investigator, makes the participant unsuitable for inclusion in the study.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:交叉作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Treatment Sequence T-R (dose 1)
Participants will receive treatment T (Chiglitazar/Metformin extended-release fixed dose combination tablets) on Day 1 followed by treatment R (Chiglitazar tablets and Metformin extended-release tablets) on Day 8. |
Chiglitazar/Metformin extended-release fixed dose combination tablets (dose 1) Chiglitazar tablets and Metformin extended release tablets (dose 1) |
|
实验性的:Treatment Sequence R-T (dose 1)
Participants will receive treatment R (Chiglitazar tablets and Metformin extended-release tablets) on Day 1 followed by treatment T (Chiglitazar/Metformin extended-release fixed dose combination tablets) on Day 8. |
Chiglitazar/Metformin extended-release fixed dose combination tablets (dose 1) Chiglitazar tablets and Metformin extended release tablets (dose 1) |
|
实验性的:Treatment Sequence T-R (dose 2)
Participants will receive treatment T (Chiglitazar/Metformin extended-release fixed dose combination tablets) on Day 1 followed by treatment R (Chiglitazar tablets and Metformin extended-release tablets) on Day 8. |
Chiglitazar/Metformin extended-release fixed dose combination tablets (dose 2) Chiglitazar tablets and Metformin extended release tablets (dose 2) |
|
实验性的:Treatment Sequence R-T (dose 2)
Participants will receive treatment R (Chiglitazar tablets and Metformin extended-release tablets) on Day 1 followed by treatment T (Chiglitazar/Metformin extended-release fixed dose combination tablets) on Day 8. |
Chiglitazar/Metformin extended-release fixed dose combination tablets (dose 2) Chiglitazar tablets and Metformin extended release tablets (dose 2) |
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
最大血浆浓度(Cmax)
大体时间:给药前及给药后72小时内多个时间点
|
给药前及给药后72小时内多个时间点
|
|
从时间零到最后一个可测量浓度的血浆浓度-时间曲线下面积 (AUC0-last)
大体时间:给药前及给药后多个时间点(最长72小时)
|
给药前及给药后多个时间点(最长72小时)
|
|
血浆浓度-时间曲线下面积从零时至无穷大(AUC0-∞)
大体时间:给药前及给药后多个时间点(最长72小时)
|
给药前及给药后多个时间点(最长72小时)
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
达峰时间(Tmax)
大体时间:给药前及给药后多个时间点(最长至72小时)
|
给药前及给药后多个时间点(最长至72小时)
|
|
消除半衰期(t1/2)
大体时间:给药前以及给药后72小时内的多个时间点
|
给药前以及给药后72小时内的多个时间点
|
|
表观总清除率 (CL/F)
大体时间:给药前以及给药后72小时内多个时间点
|
给药前以及给药后72小时内多个时间点
|
|
终末相表观分布容积(Vz/F)
大体时间:给药前及给药后多个时间点(最长至72小时)
|
给药前及给药后多个时间点(最长至72小时)
|
|
安全性评估:不良事件(AEs)发生率
大体时间:最多13天
|
最多13天
|
|
实验室安全参数相对于基线的变化(包括血液学、血清化学、凝血和尿液分析)
大体时间:至第11天
|
至第11天
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.